Los Angeles Capital Management LLC Raises Stake in Boston Scientific Corporation $BSX

Los Angeles Capital Management LLC lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 23.8% in the fourth quarter, Holdings Channel reports. The firm owned 436,183 shares of the medical equipment provider’s stock after purchasing an additional 83,769 shares during the period. Los Angeles Capital Management LLC’s holdings in Boston Scientific were worth $43,867,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth about $26,000. Murphy & Mullick Capital Management Corp grew its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the period. Colonial Trust Co SC grew its holdings in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares during the period. Bangor Savings Bank grew its holdings in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Boston Scientific during the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. Oppenheimer set a $90.00 target price on Boston Scientific in a report on Thursday, April 23rd. Barclays decreased their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Needham & Company LLC restated a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a report on Monday, May 18th. Jefferies Financial Group decreased their price target on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.92.

Boston Scientific Stock Down 0.4%

Shares of NYSE BSX opened at $48.66 on Friday. Boston Scientific Corporation has a 1 year low of $47.17 and a 1 year high of $109.50. The firm has a market cap of $72.32 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 0.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock’s 50-day simple moving average is $58.11 and its 200-day simple moving average is $76.70.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Activity

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.